

News Releases

[Register for email alerts.](#)

All Categories

Archive



Date 12/20/13

Title

Valeant Pharmaceuticals To Present At Industry Conferences

Download

[PDF](#)

Date 12/16/13

Title

Valeant Pharmaceuticals Agrees to Acquire Solta Medical for \$2.92 Per Share in Cash

Download

[PDF](#)

Date 12/13/13

Title

Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance

Download

[PDF](#)

Date 12/02/13

Title

Valeant Pharmaceuticals Announces Redemption Of The Remaining \$465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

Download

[PDF](#)

Date 11/25/13

Title

Valeant Pharmaceuticals Announces New Management Appointment

Download[PDF](#)**Date**

11/15/13

Title

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

Download[PDF](#)**Date**

11/15/13

Title

Valeant Pharmaceuticals Announced Redemption Of \$450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

Download[PDF](#)**Date**

11/15/13

Title

Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1%

Download[PDF](#)**Date**

11/15/13

Title

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

Download[PDF](#)**Date**

10/31/13

Title

Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results

Download[PDF](#)**Date**

10/28/13

Title

Valeant Pharmaceuticals Announces Settlement Agreement With Anacor

Download

PDF

Date 10/18/13

Title

Valeant Pharmaceuticals Announces Award In Anacor Dispute

Download

PDF

Date 10/08/13

Title

Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013

Download

PDF

Date 10/03/13

Title

Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada

Download

PDF

Date 10/03/13

Title

Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens

Download

PDF

Date 10/02/13

Title

Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence

Download

PDF

Date 08/09/13

Title

Valeant Pharmaceuticals Announces Continuance

Download

PDF

Date 08/07/13

Title

Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results

Download

PDF

Date 08/06/13

Title

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb

Download

PDF

Date 07/15/13

Title

Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013

Download

PDF

Date 07/02/13

Title

Medicis Announces Five-Year Aesthetic Collaboration with Mentor

Download

PDF

Date 06/27/13

Title

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

Download

PDF

Date 06/24/13

Title

Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares

Download

PDF

Date 06/20/13

Title

Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option

Download

PDF

Date

06/18/13

Title

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

Download

PDF

Date

06/18/13

Title

Valeant Pharmaceuticals Prices Public Offering Of Common Shares

Download

PDF

Date

06/17/13

Title

Valeant Pharmaceuticals Announces Public Offering Of Common Shares

Download

PDF

Date

06/07/13

Title

Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus

Download

PDF

Date

05/28/13

Title

Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole

Download

PDF

Date

05/27/13

Title

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For \$8.7 Billion

Download

PDF

Date 05/21/13

Title

Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

Download

PDF

Date 05/20/13

Title

Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference

Download

PDF

Date 05/15/13

Title

Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors

Download

PDF

Date 05/13/13

Title

Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders

Download

PDF

Date 05/10/13

Title

Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal

Download

PDF

Date 05/02/13

Title

Valeant Pharmaceuticals Provides Efinconazole Update

Download

PDF

Date 05/02/13

Title

Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results

Download**PDF****Date**

05/01/13

Title

Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel

Download**PDF****Date**

04/25/13

Title

Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.

Download**PDF****Date**

04/24/13

Title

Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.

Download**PDF****Date**

04/23/13

Title

Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.

Download**PDF****Date**

04/22/13

Title

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.

Download**PDF****Date**

04/16/13

Title

Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013

Download**PDF****Date**

04/10/13

Title

Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®

Download**PDF****Date**

04/05/13

Title

Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape

Download**PDF****Date**

04/04/13

Title

Valeant Pharmaceuticals Provides Update to Recent Event

Download**PDF****Date**

04/03/13

Title

Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of \$24.00 Per Share In Cash

Download**PDF****Date**

03/29/13

Title

Valeant Pharmaceuticals Announces Private Exchange Offer

Download**PDF****Date**

03/20/13

Title

Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for \$19.75 Per Share in Cash

Download**PDF****Date**

02/28/13

Title

Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results

Download**PDF****Date**

02/21/13

Title

Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc.

Download**PDF****Date**

02/01/13

Title

Valeant Completes Acquisition Of Natur Produkt In Russia

Download**PDF****Date**

01/31/13

Title

Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013

Download**PDF****Date**

01/03/13

Title

Valeant Pharmaceuticals Announces New Management Appointment

Download**PDF****Date**

01/02/13

Title

Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference

**Investor Inquiries**ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

[LEGAL NOTICE](#)[PRIVACY POLICY](#)[EMAIL ALERTS](#)[EMAIL PAGE](#)[RSS FEED](#)

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

Media inquiriesCorporate.communications@bauschhealth.com

908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**